This article only represents the author's own views.
Judging from the vital signs, Hong Kong’s biotech stocks have returned to rude health this year, buoyed by investor confidence in the sector.
And the robust rally in the Hang Seng Healthcare Index, which has nearly doubled since the start of year, has encouraged other medically focused companies to seek funding from the eager ranks of equity investors.
您已阅读7%（405字），剩余93%（5716字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。